CoDa's wound care product performs well in clinical trial

01/29/2013 | Interest.co.nz (New Zealand)

CoDa Therapeutics announced that its experimental drug Nexagon to treat chronic venous leg ulcers performed well in midstage clinical trials. The therapy aims to heal wounds faster and increase the incidence of wound healing compared with existing treatment options.

View Full Article in:

Interest.co.nz (New Zealand)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC